SCHEMBL1019565

SCHEMBL1019565

COc1ccc(S(=O)(=O)NCCNc2nc(Cc3ccccc3)ns2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
POLB P06746 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.48
PKM P14618 1/20 0.48
CYP19A1 P11511 1/20 0.46
GGT1 P19440 1/20 0.46
SGMS1 Q86VZ5 1/20 0.44
CA1 P00915 1/20 0.44
MAPT P10636 2/20 0.43
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1018422 0.95 ALDH1A1 (0.54) ALDH1A1POLBSMN1; SMN2PKMCYP19A1
SCHEMBL1022108 0.94 ALDH1A1 (0.55) ALDH1A1POLBSMN1; SMN2PKMCYP19A1
SCHEMBL1020309 0.91 CYP19A1 (0.49) ALDH1A1POLBSMN1; SMN2PKMCYP19A1
SCHEMBL1020764 0.91 ALDH1A1 (0.54) ALDH1A1POLBSMN1; SMN2PKMMAPT
SCHEMBL1019414 0.90 ALDH1A1 (0.58) ALDH1A1POLBSMN1; SMN2PKMMAPT
SCHEMBL1020720 0.90 MEN1 (0.51) ALDH1A1POLBSMN1; SMN2PKMCA1
SCHEMBL1018423 0.89 LMNA (0.52) ALDH1A1POLBSMN1; SMN2PKMCYP19A1
SCHEMBL1018809 0.88 ALDH1A1 (0.55) ALDH1A1POLBSMN1; SMN2PKMBRAF
SCHEMBL1021737 0.88 ALDH1A1 (0.47) ALDH1A1POLBSMN1; SMN2PKMCYP19A1
SCHEMBL1020806 0.87 GAA (0.47) ALDH1A1POLBSMN1; SMN2PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP ALDH1A1 608/4885POLB 2907/4885SMN1; SMN2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.